NEW YORK (360Dx) – RPS Diagnostics announced today its updated FebriDx test for identifying clinically significant underlying febrile acute respiratory infections has received CE marking.

The point-of-care test, which is used to help differentiate viral from bacterial infections and provides results in 10 minutes, can now be marketed in the European Union and other countries that recognize the CE mark.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.